Reading LIMN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LIMN free→Reading LIMN? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LIMN free→QuarterlyIQ Insights · LIMN
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Material Modification to Rights of Security Holders. To the extent required, the information included in
Unregistered Sales of Equity Securities. The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act available under Section 4(a)(2) and Rule 506(b) of Regulation D promulgated thereunder and such securities may not be re-offered in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and any applicable state securities laws.…
Entry into a Material Definitive Agreement. On June 3, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a warrant exercise inducement offer letter (the “Inducement Letter Agreement”) with a holder (the “Holder”) of its existing common stock warrants exercisable for an aggregate of 10,344,000 shares of its common stock (collectively, the “Existing Warrants”), to exercise its Existing Warrants at a reduced exercise price of $0.18 per share, in exchange for the Company’s agreement to is…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed in the Current Report on Form 8-K filed on November 25, 2025 with the Securities and Exchange Commission (the “SEC”), on November 19, 2025, Liminatus Pharma, Inc. (the “Company”) received notices from The Nasdaq Stock Market LLC (“Nasdaq”), indicating that the Company’s listed securities failed to comply with the $50,000,000 market value of listed securities (MVLS) requ…
Entry into Material Definitive Agreement. On May 17, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a Merger Agreement (as it may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”) with InnocsAI LLC, Delaware limited liability company (“InnocsAI”), and NamChul Jung, an individual, as the representative of the members of InnocsAI. Capitalized terms used in this Current Report on Form 8-K but not otherwise defined herein have the meanings given…
Entry into a Material Definitive Agreement. On February 17, 2026, Liminatus Pharma, Inc. (the “Company”) announced the pricing of a “best efforts” public offering of (i) 8,270,000 shares of its common stock, par value $0.0001 per share (“common stock”), (ii) 5,543,000 pre-funded warrants to purchase up to 5,543,000 shares of common stock (the “Pre-Funded Warrants”) and (ii) 13,813,000 common stock purchase warrants to purchase up to 20,719,500 shares of common stock (the “Warrants”), at a com…
Entry into a Material Definitive Agreement. On February 6, 2026, Liminatus Pharma, Inc. (the “Company”) entered into a settlement and release agreement (the “Settlement Agreement”) with Clear Street LLC (the “Holder”), pursuant to which the Company agreed to issue 4,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Holder in exchange for the surrender and cancellation of 805,377 warrants (the “Warrants”) to purchase shares of Common Stock…
Unregistered Sales of Equity Securities. The information set forth under
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 15, 2026, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price for the last 30 consecutive business days, the Company was no longer in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) which requires listed securities t…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 19, 2025, Liminatus Pharma, Inc. (the “Company”) received notices from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with (i) Nasdaq Listing Rule 5450(b)(2)(A) due to its failure to maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 (the “MVLS Rule”), based upon a review of…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 22, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (the “Form 10-Q”). The deficiency letter has no im…
Entry into a Material Definitive Agreement. On July 16, 2025, Liminatus Pharma, Inc. (the “Company”) entered into a settlement and release agreement (the “Settlement Agreement”) with Alta Partners, LLC (the “Holder”), pursuant to which the Company agreed to issue 350,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (“Common Stock”), to the Holder in exchange for the surrender and cancellation of 1,000,000 warrants (the “Warrants”) to purchase shares of Common Stock h…
Unregistered Sales of Equity Securities. The information set forth under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 10, 2025, the board of directors (the “Board”) of Liminatus Pharma, Inc. (the “Company”) increased the size of the Board to six (6) members and appointed Philip Lemons and Richard Baek as directors of the Company, effective immediately. Philip Lemons, 54, brings extensive expertise in clinical research and development, with over two decades…
Other Events Liminatus Pharma, Inc. has entered into a Memorandum of Understanding (MOU) to form a research and development consortium with Samda Biolab Co., Ltd. and INNOCS AI, aimed at advancing a novel blood-based diagnostic kit for early detection of pancreatic cancer. Liminatus Pharma recognizes the groundbreaking potential of the CA19-9-combined INNOCS diagnostic platform jointly developed by Samda and INNOCS AI, and has resolved to actively participate in the R&D consortium with a view…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 29, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”)…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.